摘要
目的 探讨ATD(抗甲状腺药物 )对Graves’病13 1I治疗疗效的影响程度 ,指导临床更加合理地使用13 1I治疗剂量 .方法 选取 80例已服用ATD的Graves’病患者按停服ATD时间长短分成 4组 .全部行吸碘率检查及13 1I治疗 ;再按服用ATD时间长短分为 3组 ,以 2 0例未服ATD即行13 1I治疗者为对照组 ,比较 2 4小时最高吸碘率及13 1I治疗疗效.结果 未服用ATD者 2 4小时最高吸碘率和13 1I治愈率最高 ,停用ATD时间越短 ,最高吸碘率和治愈率越低 ;服用ATD时间越长 ,13 1I治疗的疗效越差 .结论 ATD能较明显影响Graves’病13 1I的疗效 ,是13
Objective To investigate the influence of ATD on 131 I treatment in Graves' disease and to evaluate reasonable dosage of 131 I for the treatment of Graves' disease. Methods 80 cases of Graves' disease had been treated with ATD and they were divided into four groups. the first group stoped taking ATD 7 days before 131 I treatment;the second group stoped at 15 days before 131 I treatment;the third group stoped taking ATD beyond 15 days before 131 I treatment;the fourth group continued to take ATD.All the patients received examination for thyroid putake Ratio (TUR) absorption and 131 I treatment. The following treatment were divided into 3 groups:the first group had taken ATD less than 1 year,the second group had taken ATD for 1~5 years;the third group had taken ATD over 5 years;and 20 cases had not taken ATD when they visited doctor but treated by 131 I were set as control. Iodine absorption peak and 131 I treatment effects were evaluated. Results Patients had not taken ATD b ut treated by 131 I had the highest iodine absorption peak and cured rate,the shorter time of stop taking ATD,the lower of iodine absorption peak and cure rate;the longer time of taking ATD,the worse effects of 131 I treatment. Conclusion ATD could apperently effect the therapeutical effec ts of 131 I treatment of Graves' disease,and It is a factor must be comprehensively considered when 131 I treatment is applied.
出处
《现代临床医学生物工程学杂志》
2004年第1期37-38,共2页
Journal of Modern Clinical Medical Bioengineering